COVID-19 vaccination immune paresis in heart and lung transplantation
- PMID: 34144891
- PMCID: PMC8116313
- DOI: 10.1016/j.healun.2021.04.018
COVID-19 vaccination immune paresis in heart and lung transplantation
Keywords: COVID-19; immune paresis; immunosuppression; transplantation; vaccine effectiveness.
Conflict of interest statement
Conflict of Interest SA: Grant funding from the Cystic Fibrosis Foundation. Consultant for Merck, Gilead and BioMx. LD: Consultant for Merck, Takeda. Contracted Clinical research support from Astellas, Ansun biopharma, Merck, Takeda, and Viracor M.R.M - payment made to institution from Abbott for consulting. Consulting fees from Mesoblast, Janssen, Portola, Bayer, Triple Gene, and Baim Institute for Clinical Research. Advisory board member for NuPulseCV, Leviticus and FineHeart.
Comment on
-
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.J Heart Lung Transplant. 2021 Aug;40(8):759-762. doi: 10.1016/j.healun.2021.04.003. Epub 2021 Apr 21. J Heart Lung Transplant. 2021. PMID: 34034958 Free PMC article.
-
Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.J Heart Lung Transplant. 2021 Aug;40(8):754-758. doi: 10.1016/j.healun.2021.05.004. Epub 2021 May 21. J Heart Lung Transplant. 2021. PMID: 34120839 Free PMC article.
References
-
- Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382:1969–1973. - PubMed
-
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical